Vaccines are one of the most effective medical interventions to combat newly emerging and
re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent …

This year marks the 50th anniversary of the discovery of the Australia antigen (Blumberg et
al., 1965), which in 1967 was identified to be the hepatitis B virus (HBV) surface antigen …

More than 250 million people worldwide are chronically infected with hepatitis B virus
(CHB), and over half a million die each year due to CHB-associated liver complications such …

The evolution of the H5 highly pathogenic avian influenza (HPAI) viruses has led to the
emergence of distinct groups with genetically similar clusters of hemagglutinin (HA) …

This review article is a continuation of the paper “Hepatitis B core particles as a universal
display model: a structure-function basis for development” written by Pumpens P. and Grens …

Chronic hepatitis B virus (HBV) infection is a public health challenge worldwide. Antiviral
agents (nucleos (t) ide analogues, NAs) and immune-based therapies (IFN-α or Pegylated …

Background: Infection with the hepatitis B virus (HBV) is one of most important risk factors for
hepatocellular carcinoma (HCC). Indeed, HBV is considered a group 1 human carcinogen …

Introduction: With at least 240 million hepatitis B virus (HBV) carriers worldwide, being at a
high risk of cirrhosis and hepatocellular carcinoma (HCC), chronic hepatitis B remains a …

Background Seroclearance of hepatitis B surface antigen (HBsAg) has been rarely achieved
in the treatment of chronic hepatitis B (CHB) patients. We administered HBsAg-based …

There are well over a quarter of a billion chronic hepatitis B virus (HBV) carriers across the
globe. Most carriers are at high risk for development of liver cirrhosis and subsequent …